Blog
RSS FeedPosted by Michael Wonder on 22 Oct 2018
Pharmaceutical pricing conundrum: time to get rid of it?
21 October 2018 - A basic concept of economics is that a price stems from the intersection between supply and demand ...
Posted by Michael Wonder on 20 Oct 2018
Is the EUnetHTA HTA core model fit for purpose? Evaluation from an industry perspective
18 October 2018 - The HTA Core Model was developed to improve the transferability of health technology assessment between settings. ...
Posted by Michael Wonder on 10 Oct 2018
New drugs: how much are governments paying for innovation?
10 October 2018 - The medical innovation debate is also heated up due to the ongoing discussion on Health Technology Assessments. ...
Posted by Michael Wonder on 01 Oct 2018
Pertuzumab in early breast cancer: no proof of an additional benefit despite exemplary surrogate validation
1 October 2018 - Effect on disease-free survival too small to conclude on overall survival. ...
Posted by Michael Wonder on 12 Sep 2018
A breakthrough cancer drug has been approved. Now comes the battle over the price.
12 Septemner 2018 - Novartis' breakthrough cancer drug Kymriah has been approved in Europe. Now comes the debate about its ...
Posted by Michael Wonder on 06 Aug 2018
Division on European HTA
3 August 2018 - There have been aspirations for closer collaboration between European Union Member States on health technology assessment for ...
Posted by Michael Wonder on 13 Jul 2018
Getting it right: EPHA recommendations on how to improve the European Commission proposal on health technology assessment
11 July 2018 - The European Public Health Alliance welcomes the European Commission proposal for a regulation on health technology ...
Posted by Michael Wonder on 02 Jul 2018
Haemophilia A and sialorrhoea: contemporary comparative therapies not implemented so added benefit not proven
2 July 2018 - Of the four dossier evaluations published by the IQWiG on 2 July, two have a striking similarity ...
Posted by Michael Wonder on 24 Jun 2018
Industry urges EU to scrap national HTA bodies
22 June 2018 - The pharma industry has called for European member states’ national drug value assessment bodies to be ...
Posted by Michael Wonder on 21 Jun 2018
Confirmatory versus explorative endpoint analysis: decision-making on the basis of evidence available from market authorisation and early benefit assessment for oncology drugs
21 June 2018 - The early benefit assessment of pharmaceuticals in Germany and their preceding market authorisation pursue different objectives. ...
Posted by Michael Wonder on 14 Jun 2018
Effect of cross-over in oncology clinical trials on evidence levels in early benefit assessment in Germany
13 June 2018 - In oncology clinical trials, cross-over is used frequently but may lead to uncertainties regarding treatment effects. ...
Posted by Michael Wonder on 13 Jun 2018
Metastatic breast cancer: highly selective post-hoc analysis rather than complete publication of quality of life data
13 June 2018 - IQWiG employees criticise the publication practice of PALOMA-2 study authors. ...
Posted by Michael Wonder on 13 Jun 2018
Janssen’s Tremfya (guselkumab) receives its first two positive Health Technology Assessments in Europe
13 June 2018 - The United Kingdom’s NICE publishes positive guidance for the first selective interleukin 23 inhibitor to treat moderate ...
Posted by Michael Wonder on 11 Jun 2018
Rheumatoid arthritis: few indications of the benefits of certain biologics over others
6 June 2018 - Still no long-term studies and little direct comparisons of biologics/first-time also first-line therapy examined. ...
Posted by Michael Wonder on 04 Jun 2018
English translation of IQWiG’s updated General Methods now available
4 June 2018 - New chapters on HTA reports addressing topics proposed by the public and on the assessment of ...